On the contrary, the anti-CD47 “don’t eat me” antibody magrolimab was associated with promising responses in a phase 1b trial (NCT03248479) where combination therapy of magrolimab and azacitidine demonstrated durable responses and a benefit in overall survival in a cohort of patients with treatment naïve AML harboring TP53-mutated AML who were unsuitable for intensive chemotherapy [39]. Here, TP53 is linked to acute myeloid leukemia.